Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Insights on Key Data From ASH 2020 on Nonmalignant Hematologic Disorders

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
In this podcast episode, listen to Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD, discuss their takeaways on new data presented at ASH 2020 in nonmalignant hematologic diseases, including studies on disorders of bleeding and clotting, hemoglobinopathies, and GVHD.
Hanny Al-Samkari, MD
Mark A. Schroeder, MD
Sujit Sheth, MD
Released: February 10, 2021

In this episode, Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD, provide their clinical perspectives on new data from ASH 2020 on nonmalignant hematologic disorders, with topics including:

  • Use of mycophenolate mofetil plus corticosteroids vs standard corticosteroid treatment in patients with ITP from the phase III FLIGHT study
  • Analysis of an ongoing phase I/II trial of rilzabrutinib reporting safety and efficacy in the long-term extension for adult patients with relapsed/refractory ITP
  • New data from the phase III HOPE-B study of etranacogene dezaparvovec gene therapy, using an AAV5-vector to deliver the Padua variant of the factor IX gene in patients with hemophilia B
  • An update from the phase I/II CLIMB THAL-111/SCD-121 studies reporting safety and efficacy on the first 10 patients receiving CTX001 with at least 3 months of follow-up
  • Primary analysis from the phase III REACH3 trial evaluating ruxolitinib, an oral JAK1/2 inhibitor, in combination with steroids and calcineurin inhibitors, as a treatment for steroid-refractory or steroid-dependent chronic GVHD
  • Top-line results from the phase II ROCKstar study of belumosudil, a ROCK2 kinase inhibitor, in patients with heavily pretreated chronic GVHD
  • Phase I data from the GRAVITAS-119 study of JAK1 inhibitor itacitinib plus calcineurin inhibitors as prophylaxis treatment for acute GVHD

Presenters:

Hanny Al-Samkari, MD
Instructor
Department of Medicine
Harvard Medical School
Attending Hematologist and Clinical Investigator
Division of Hematology Oncology
Massachusetts General Hospital
Boston, Massachusetts

Sujit Sheth, MD
Professor
Department of Pediatrics
Weill Cornell Medicine
New York, New York

Mark A. Schroeder, MD
Associate Professor of Medicine
Division of Oncology
Department of Medicine
Washington University School of Medicine in St Louis
St Louis, Missouri

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech, Inc.
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

On-demand webcast from a satellite symposia at the 2021 Hematology meeting on diagnosis and management of aTTP, from Clinical Care Options (CCO)

Ara Metjian, MD
Program Director
Paul Coppo, MD, PhD Marshall Mazepa, MD
Physicians: maximum of 1.75 AMA PRA Category 1 Credits Released: January 26, 2022 Expired: January 25, 2023

Download this short slideset from Clinical Care Options (CCO) on the management of newly diagnosed and relapsed light-chain (AL) amyloidosis

Ankit Kansagra, MD Shaji K. Kumar, MD Vaishali Sanchorawala, MD Released: January 19, 2022

Downloadable PDF summary transcript of expert answers to questions on hemophilia A management, from Clinical Care Options (CCO)

Miguel A. Escobar, MD Mark Reding, MD Guy A. Young, MD Released: January 18, 2022

Podcast with expert insight on the use of current and emerging treatments for patients with hemophilia A, from Clinical Care Options (CCO)

Miguel A. Escobar, MD
Program Director
Mark Reding, MD Guy A. Young, MD
Released: January 14, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings